News

The company completes part of the experiments with photocontrolled anti-cancer compounds at the facilities of Ukrainian partner Enamine Ltd. The study was planned for Feb-Mar 2022. Research became impossible due to Russia's treacherous military aggression against Ukraine. The Ukrainian part of our team, Prof. Igor V. Komarov and Dr. Sergii Afonin, are currently in Kyiv and witnessing unprecedented vandalism of the Russian armed forces, resulting in civilians' deaths and a humanitarian catastrophe.

We will continue working with Ukrainian colleagues on the data already obtained and are developing plans for further experiments. Ukraine will overcome this aggression! There is no doubt about it, just as there is no doubt that humanity will overcome cancer one day.

The power of our technology platform was demonstrated once more by the design of photocontrollable serine protease inhibitors. The prototype peptide, a natural trypsin inhibitor SFTI-1 (SunFlower Trypsin Inhibitor-1) was used as a template for the design of bicyclic diarylethene-containing peptidomimetics, whose inhibiting activity could be modulated up to 35-fold by photoswitching. The work was published in Angewandte Chemie at 10.1002/anie.202108847

We are happy to announce the start of Project ALISE supported by European Commission under Horizon 2020 MSCA-RISE. As part of an international consortium Lumobiotics is involved in the development of light-controllable antibody peptide conjugates pushing the boundaries of photopharmacology towards clinical applications.